國家衛生研究院 NHRI:Item 3990099045/15707

NHRI > Institute of Biotechnology and Pharmaceutical Research > Lun Kelvin Tsou > Periodical Articles > Item 3990099045/15707

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15707

Title:	Immunomodulatory and anti-angiogenesis effects of excavatolide B and its derivatives in alleviating atopic dermatitis
Authors:	Chen, HW;Liu, FC;Kuo, HM;Tang, SH;Niu, GH;Zhang, MM;Tsou, LK;Sung, PJ;Wen, ZH
Contributors:	Institute of Biotechnology and Pharmaceutical Research;Institute of Molecular and Genomic Medicine
Abstract:	Atopic dermatitis (AD) is a chronic inflammatory skin condition primarily driven by T helper 2 (Th2) cytokines, resulting in skin barrier defects, angiogenesis, and inflammatory responses. The marine natural product excavatolide B (EXCB), isolated from the Formosan Gorgonian coral Briareum stechei, exhibits anti-inflammatory and analgesic properties. To enhance solubility, EXCB is chemically modified into the derivatives EXCB-61 salt and EXCB-79. The study aims to investigate the therapeutic effects of these compounds on dinitrochlorbenzene (DNCB)-induced skin damage and to elucidate the underlying anti-inflammatory and anti-angiogenesis mechanism. In vitro, using lipopolysaccharide (LPS)-induced RAW 264.7 cells, all compounds at 10 μM significantly inhibited expression of inflammatory proteins (inducible nitric oxide synthase and cyclooxygenase-2), vascular endothelial growth factor (VEGF), and cytokines (interleukin (IL)−1β, IL-6, and IL-17A). In vivo, topical application of these compounds on DNCB-induced AD mice alleviated skin symptoms, reduced serum levels of IgE, IL-4, IL-13, IL-17, and interferon-γ, and moderated histological phenomena such as hyperplasia, inflammatory cell infiltration, and angiogenesis. The three compounds restored the expression of skin barrier-related proteins (loricrin, filaggrin, and claudin-1) and reduced the expression of angiogenesis-related proteins (VEGF and platelet endothelial cell adhesion molecule-CD31) in the tissues. This is the first study to indicate that EXCB, EXCB-61 salt, and EXCB-79 can treat AD disease by reducing inflammation and angiogenesis. Hence, they may be considered potential candidates for the development of new drugs for AD.
Date:	2024-03
Relation:	Biomedicine and Pharmacotherapy. 2024 Mar;172:Article number 116279.
Link to:	http://dx.doi.org/10.1016/j.biopha.2024.116279
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0753-3322&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001188646600001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85185339360
Appears in Collections:	[Lun Kelvin Tsou] Periodical Articles [Mingzi M. Zhang] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85185339360.pdf		13504Kb	Adobe PDF	177	View/Open

Loading...